KIT and cancer: The authors of this study identified several receptor tyrosine-protein kinases (RTK) in the drug resistance of NSCLC cells, including ERRB4, KIT, and Tie1, and suggested that the inhibition of RTKs may sensitize cancer cells to paclitaxel.